What the 2026 OIG Lab Spending Data Means for Laboratory Revenue Cycle Management – and Why the Compliance Picture Just Changed

For clinical laboratory and pathology executives, 2026 presents a reimbursement landscape that looks fundamentally different depending on which tests your organization primarily performs.

The Office of Inspector General released its January 2026 analysis of Medicare Part B laboratory spending – and the headline figure requires context to be useful [1]. Total Part B lab spending rose 5% to $8.4 billion in 2024. But that increase came from genetic testing, which now accounts for 43% of all Part B lab spending at $3.6 billion – despite representing only 5% of all tests performed. In 2018, genetic tests accounted for just 18% of Part B lab spending. The shift over six years is the most significant structural change in Medicare lab reimbursement in the PAMA era.

Meanwhile, non-genetic tests – the metabolic panels, lipid panels, and complete blood cell counts that constitute the majority of routine lab volume – have been declining since 2021, reaching $4.8 billion in 2024. The top 25 lab tests accounted for nearly half of all Part B lab spending, exceeding $4.1 billion, with the single highest-expenditure test – a genetic test – carrying a median payment of $447 per claim [1].

Critically, this spending growth is not driven by CLFS rate increases. Under PAMA, the Clinical Laboratory Fee Schedule has been largely frozen since 2020. The increase reflects utilization changes and test mix shifts – which is precisely why OIG is now actively monitoring the pattern.

On June 15, 2026, the OIG announced a new Work Plan project titled Trends and Vulnerabilities in Genetic Tests Covered Under Medicare Part B (OEI-09-26-00270) [2].

The project's stated rationale: "Medicare Part B spending on genetic tests has been climbing steadily, with 2024 expenditures topping $3.6 billion – a half-billion-dollar increase over the previous year. The rapid emergence of new tests and the higher average per-test payment amount can also make genetic tests vulnerable to fraud, waste, and abuse.” [2]

This is the enforcement escalation that the January 2026 spending data foreshadowed. The spending analysis was descriptive. The June 2026 Work Plan project is investigative. For laboratories with significant molecular and genetic testing volume, this signals that billing documentation, LCD compliance, and ordering physician documentation standards are now active audit priorities – not future considerations.

The OIG data reveals two distinct financial environments coexisting in the laboratory market – each requiring a different billing infrastructure response.

For labs performing significant genetic and molecular testing volume:

• High per-claim values ($447 median for the top genetic test) make every documentation and coding error individually consequential
• The June 2026 OIG Work Plan project places LCD compliance and medical necessity documentation on active investigative review
• Prior authorization requirements from Medicare Advantage and commercial payers require complete clinical documentation at the first request – not supplemented after the fact
• Ordering physician documentation of clinical indication must be contemporaneous, specific, and aligned to the LCD criteria for each test

For labs performing predominantly routine non-genetic testing:

• Per-enrollee payment trends are declining even as fixed operating costs rise
• CLFS rates have been largely frozen since 2020 under PAMA provisions – note: Congress included a one-year delay to scheduled PAMA-triggered rate cuts in a 2026 appropriations bill, providing temporary relief
• The July 31, 2026 CLFS data reporting deadline is two weeks away – labs that have not yet submitted private payer rate data need to act immediately. The accuracy of HCPCS code mapping and payment data submitted in this cycle directly shapes Medicare reimbursement rates in future years

Both environments create material laboratory revenue cycle management risk – but the risks are different, and the billing infrastructure required to manage them must reflect that difference.

Under the Protecting Access to Medicare Act (PAMA), Medicare CLFS rates are based on weighted median private payer rates reported by applicable laboratories during defined data collection periods [3].

The July 31, 2026 reporting deadline is approaching. For applicable laboratories – independent labs, physician office labs, and hospital outreach labs meeting the applicable criteria – this is not an administrative formality. The private payer rates, HCPCS codes, and volume data submitted in this cycle will directly influence what Medicare pays in future rate periods.

Common reporting errors that affect reimbursement outcomes:

• HCPCS code mapping errors: submitting data under incorrect codes misrepresents actual payment rates
• Incomplete volume data: understating or overstating claims volume affects the weighted median calculation
• Misclassified payment amounts: including write-offs, contractual adjustments, or secondary payer payments incorrectly

Strong clinical lab billing services include PAMA compliance infrastructure – applicability determination, code mapping verification, data submission workflows, and post-submission review – that connects reporting accuracy to long-term reimbursement performance.

For labs that have not yet submitted data, the July 31 deadline is two weeks away. For labs that have submitted, post-submission review of the data for completeness and accuracy before the window closes is the current priority.

Laboratory revenue cycle management spans patient registration, insurance verification, order documentation, HCPCS and CPT coding, ABN validation, LCD alignment, claims submission, payment posting, denial management, underpayment recovery, and reimbursement analytics. What has changed in 2026 is the performance standard each of those functions must meet – particularly for genetic and molecular testing, where OIG is now conducting an active investigation.

An effective laboratory revenue cycle management program generates financial intelligence that executive leadership can act on. The following KPIs provide a more accurate picture of organizational financial health than reimbursement rates alone:

• First-pass claim acceptance rate: target above 95%; every point below signals upstream order or coding failures
• Denial rate separated by payer and test category: genetic test denials and routine test denials have different root causes and require different corrective action
• Days in accounts receivable by payer type: commercial, Medicare, and Medicare Advantage have materially different expected timelines
• LCD compliance rate: percentage of molecular and genetic test claims with complete, contemporaneous medical necessity documentation at the time of submission
• Underpayment recovery rate: particularly important for genetic tests where payer-specific contract rates vary significantly
• Net collection rate: adjusted for contractual allowances; should reflect actual reimbursement against expected contracted payment
• Cost to collect: rising cost-to-collect against declining non-genetic test revenue signals a structural billing efficiency problem

Pathology organizations operate within a subset of the lab billing environment with additional complexity: multiple procedure component billing, technical and professional component separation, surgical pathology level coding (CPT 88300–88309), cytopathology, and molecular pathology billing.

The OIG's focus on genetic test spending is directly relevant to pathology groups performing molecular pathology, next-generation sequencing, and genomic testing. These services carry the highest per-claim values in the lab market – and the highest documentation burden under current Medicare coverage requirements.

Specialized pathology billing services help pathology organizations:

• Code surgical pathology levels accurately and consistently across all pathologists in the group
• Manage technical and professional component billing for hospital-based and independent practices
• Apply payer-specific rules for molecular pathology and genomic tests aligned to current LCDs
• Validate medical necessity documentation before claims submit – not after denials arrive
• Track denial patterns by test type and payer to identify specific billing workflow gaps

For an independent assessment of pathology revenue cycle health across these categories, see The Pathology Revenue Health Check: 15 Questions Every Pathology Organization Should Ask.

The OIG's January 2026 data and its June 2026 enforcement project together define the compliance and financial landscape for laboratory billing in the second half of 2026. The organizations best positioned are those acting now – before the July 31 CLFS deadline closes, before the OIG genetic testing investigation produces findings, and before any future CLFS rate adjustments take effect.

Five strategic priorities for laboratory and pathology revenue cycle leaders:

1. Submit or verify CLFS reporting data before July 31, 2026. The current deadline closes in two weeks. Applicable laboratories that have not submitted, or that submitted without verifying HCPCS code accuracy and volume completeness, should act immediately.

2. Conduct a genetic test billing compliance review. The OIG's June 2026 Work Plan project specifically targets genetic test billing. Labs performing significant molecular and genetic testing volume should audit LCD compliance, ordering physician documentation, and medical necessity support for these claims before an external review arrives.

3. Separate your revenue cycle strategy by test category. Genetic and molecular testing requires different billing workflows, different LCD monitoring cadences, and different documentation standards than routine chemistry and hematology. Organizations applying a single billing model to both are creating preventable exposure on their highest-value claims.

4. Build real-time denial visibility by test type and payer. Knowing your total denial rate is not sufficient. Knowing your denial rate for genetic tests by payer – and which specific denial reasons are appearing – is what allows corrective action before the pattern compounds.

5. Review underpayment exposure on high-value molecular tests. The gap between contracted rates and actual payments on molecular and genetic tests is one of the most commonly underidentified revenue recovery opportunities in laboratory billing. A targeted underpayment analysis on the test categories OIG has flagged is a high-return investment of billing team time.

At 3Gen Consulting, laboratory revenue cycle management services are built around the specific billing, coding, and compliance requirements of clinical labs and pathology organizations – including PAMA-aligned CLFS reporting support, LCD compliance workflows for molecular and genetic testing, and pathology billing services covering the full complexity of surgical pathology, cytopathology, and molecular pathology billing. RevGen-i provides real-time analytics across payers, test categories, and denial types – giving laboratory leadership the visibility to manage revenue as a strategic function.

The July 31 CLFS deadline is two weeks away. The OIG genetic testing enforcement project is active. The labs that are best prepared are those that already have billing infrastructure matched to the environment. Schedule a laboratory revenue cycle assessment with 3Gen →